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Abstract
There is substantial experimental evidence for dysregulation of several microRNA (miRNA) expression levels in
Alzheimer’s disease (AD). MiRNAs modulate critical brain intracellular signaling pathways and are associated with AD
core pathophysiological mechanisms. First, we conducted a real-time quantitative PCR-based pilot study to identify a
set of brain-enriched miRNAs in a monocentric cohort of cognitively normal individuals with subjective memory
complaints, a condition associated with increased risk of AD. Second, we investigated the impact of age, sex, and the
Apolipoprotein E ε4 (APOE ε4) allele, on the identified miRNA plasma concentrations. In addition, we explored the
cross-sectional and longitudinal association of the miRNAs plasma concentrations with regional brain metabolic
uptake using amyloid-β (Aβ)-positron emission tomography (Aβ-PET) and 18F-fluorodeoxyglucose-PET (18F-FDG-PET).
We identified a set of six brain-enriched miRNAs—miRNA-125b, miRNA-146a, miRNA-15b, miRNA-148a, miRNA-26b,
and miRNA-100. Age, sex, and APOE ε4 allele were not associated with individual miRNA abundance. MiRNA-15b
concentrations were significantly lower in the Aβ-PET-positive compared to Aβ-PET-negative individuals. Furthermore,
we found a positive effect of the miRNA-15b*time interaction on regional metabolic 18F-FDG-PET uptake in the left
hippocampus. Plasma miRNA-125b concentrations, as well as the miRNA-125b*time interaction (over a 2-year follow-
up), were negatively associated with regional Aβ-PET standard uptake value ratio in the right anterior cingulate cortex.
At baseline, we found a significantly negative association between plasma miRNA-125b concentrations and 18F-FDG-
PET uptake in specific brain regions. In an asymptomatic at-risk population for AD, we show significant associations
between plasma concentrations of miRNA-125b and miRNA-15b with core neuroimaging biomarkers of AD
pathophysiology. Our results, coupled with existing experimental evidence, suggest a potential protective anti-Aβ
effect of miRNA-15b and a biological link between miRNA-125b and Aβ-independent neurotoxic pathways.
Introduction
MicroRNAs (miRNAs)—a class of endogenous, single-
stranded, 22-ribonucleotide-average-sized, non-coding
RNAs—modulate post-transcriptional gene expression
by either repressing translation or degrading their target
messenger RNAs (mRNAs) after binding to the mRNAs
3′-untranslated region1,2. In the brain and central nervous
system (CNS) miRNAs appear to act as single-discrete
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single-stranded RNA molecules or may be encapsulated
into plasma membrane-derived exosomes (EXs) or
extracellular microvesicles3.
In the brain—including the neocortex, hippocampus,
and the limbic system—miRNAs regulate several intra-
cellular signaling pathways involved in synaptic home-
ostasis, neuronal bioenergetics activity, and protein/lipid
homeostasis4,5. In general, miRNA expression patterns are
complex and dynamic; for instance, the natural miRNA
abundance is subject to alterations during neural devel-
opment and differentiation of the human brain and in the
CNS during aging6–8.
Experimental models of aging and Alzheimer’s disease
(AD), as well as in-human post-mortem and in vivo
biomarker-based studies, indicate that the dysregulation
of several miRNAs may influence AD pathophysiological
mechanisms, including the amyloid-β (Aβ) pathway, tau
pathology, brain immune, and inflammatory response,
oxidative stress regulation, among others7–16.
Emerging data encourage further analysis and char-
acterization of specific miRNAs that may be either
downregulated or upregulated aberrantly in the pro-
dromal and preclinical phases of AD7,8,14–16, where
treatments with putative disease-modifying effect are
more likely to be effective17–19.
Although abnormal miRNA patterns are exhaustively
explored in AD cell culture models20–25 and patients’
tissue samples26,27, less information is available on
extracellularly secreted miRNAs circulating in the per-
ipheral blood, referred to as “circulating miRNAs”. They
are either encapsulated by extracellular vesicles, such as
EXs and microvesicles or bound to molecules such as the
Argonaute protein or high-density lipoprotein choles-
terol28–32.
In the present pilot study, we identified a set of six
brain-enriched miRNAs (either brain-specific or highly
expressed in the brain)—namely, miRNA-125b, miRNA-
146a, miRNA-15b, miRNA-148a, miRNA-26b, and
miRNA-100—in the INISGHT-preAD study cohort, a
monocentric cohort of cognitively normal individuals
with subjective memory complaint (SMC), a condition
associated with increased risk of sporadic AD33–35.
We sought to examine the impact of primary biological
factors–age, sex, and apolipoprotein E (APOE) ε4 allele—
on plasma concentrations of the selected miRNA set.
Subsequently, we performed an exploratory study, both
cross-sectional and longitudinal, to investigate whether
baseline concentrations of these six miRNAs are asso-
ciated with established neuroimaging biomarkers of AD
pathophysiology, namely (I) Aβ-positron emission tomo-
graphy (Aβ-PET), at both global and regional level, and
(II) 18F-fluorodeoxyglucose-PET (18F-FDG-PET) to assess
neuronal metabolism.
Materials and methods
Study participants and cognitive assessment
Sixty individuals with SMC were recruited from the
standardized, large-scale, observational, monocentric,
French academic university-based “INveStIGation of
AlzHeimer’s PredicTors in Subjective Memory Complai-
ners” (INSIGHT-preAD) study35, that is part of the Alz-
heimer Precision Medicine Initiative (APMI) and its
established Cohort Program (APMI-CP)36. Participants
were enrolled at the Institute of Memory and AD (Institut
de la Mémoire et de la Maladie d’Alzheimer, IM2A) at the
Pitié-Salpêtrière University Hospital in Paris, France.
The main objective of the INSIGHT-preAD study is to
explore the earliest preclinical stages of AD and their
progression to incipient objective cognitive impairment,
using comprehensive clinical parameters and multi-modal
biomarkers.
In brief, the INSIGHT-preAD study includes 318 cog-
nitively and physically normal Caucasian individuals,
recruited from the community in the wider Paris area,
France, aged 70 to 85, with SMC. The status of SMC was
confirmed as follows: (I) participants gave an affirmative
answer (“YES”) to both questions: “Are you complaining
about your memory?” and “Is it a regular complaint that
has lasted for more than 6 months?”; (II) participants
showed intact cognitive functions based on the Mini-
Mental State Examination score (MMSE, ≥ 27), Clinical
Dementia Rating scale (CDR= 0), and Free and Cued
Selective Rating Test (FCSRT, total recall score ≥41).
Aβ-PET imaging investigation was performed at the
baseline visit, as a mandatory inclusion criterion. Thus, all
individuals enrolled in the study have SMC and are stra-
tified as either positive or negative for brain Aβ deposi-
tion. At baseline, demographic, clinical data, and APOE
genotype (See Supplementary material) were collected in
all participants. Exclusion criteria were a history of neu-
rological or psychiatric diseases, including depressive
disorders.
The study was conducted in accordance with the tenets
of the Declaration of Helsinki of 1975 and approved by
the local Institutional Review Board at the participating
center (Ethical approval number: 2013-Fev-13150). All
participants or their representatives gave written
informed consent for the use of their clinical data for
research purposes.
Blood sampling and collections of tube storage
Ten (10) mL of venous blood were collected in one BD
Vacutainer® tube (lithium heparin), which was employed
for subsequent analyses. Blood samples were taken in the
morning, after a 12-hour fast, handled in a standardized
way, and centrifuged for 15minutes at 2000 G-force at 4 °C.
Per sample, plasma fraction was collected, homogenized,
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aliquoted into multiple 0.5mL cryovial-sterilized tubes, and
finally stored at –80 °C within 2 hours from collection.
Data for plasma concentrations of the six miRNAs were
collected at participants’ enrollment (“baseline visit” or
“M0”).
Total RNA isolation from human plasma
Plasma samples from age- and sex-matched SMC
individuals (N= 60), dichotomized according to the
Aβ-PET imaging status—either positive (N= 30) or
negative (N= 30)—were selected for the analysis. Samples
were thawed slowly on ice, and total RNA was isolated
from 200 μL of plasma using a miRNeasy Serum/Plasma
Advanced Kit (Qiagen, Germantown, MD) according to
the manufacturer’s instructions for liquid samples. To
allow for normalization of sample-to-sample variation in
RNA isolation, 3.5 μL of 1.6 × 108 copies/μL of synthetic
Caenorhabditis elegans miRNA cel-miRNA-39 (Qiagen)
was added to each sample right after the addition of lysis
buffer (buffer RPL), during the first steps of the RNA
isolation protocol. RNA was, then eluted with 20 μL of
H2O according to the manufacturer’s instructions.
Measurement of plasma miRNAs concentration
The samples were treated with heparinase during the
reverse transcription (RT) step, as previously described
elsewhere37, to overcome the inhibition from residual
heparin to downstream real-time quantitative PCR (qRT-
PCR) reactions. In brief, 0.25 μL of RNA was reverse-
transcribed using the TaqMan High-Capacity cDNA
Reverse Transcription Kit and miRNA-specific RT stem-
loop primers (Thermo Fisher Scientific, Waltham, MA) in
a 15-μL RT reaction containing 0.25 μL of the RNA
extract, 0.15 μL of 100mM dNTP, 1.0 μL of MultiScribe™
reverse transcriptase (50 U/μL), 1.5 μL of 10× RT buffer,
0.19 μL of RNase inhibitor (20 U/μL), 3.0 μL of 5×
miRNA-specific stem-loop RT primer, 8.4 μL of RNase-
free water and 0.5 μL of Bacteroides Heparinase I (12 U/
μL) (New England Biolabs, Ipswich, MA). The reaction
mixture was first incubated at 37 °C for 1 h for heparinase
digestion, followed by RT reactions at 16 °C for 30 min, at
42 °C for 30min, and at 85 °C for 5 min, and then main-
tained at 4 °C. The complementary DNA (cDNA) pro-
ducts were stored at −20 °C until analysis.
For qRT-PCR, the RT products were diluted 3× prior to
qRT-PCR. In all, 2 μL of the diluted cDNA product was
employed as a template in a 20-μL reaction containing
1.0 μL of TaqMan miRNA Assay (Thermo Fisher Scien-
tific), 7.67 μL of RNase-free water, and 10 μL of TaqMan™
Universal Master Mix II, with UNG (Thermo Fisher Sci-
entific). The qRT-PCR was performed with Bio-Rad
CFX96 real-time PCR system (Bio-Rad) at 95 °C for
10min, followed by 40 cycles of 95 °C for 15 s and 60 °C
for 1 min (see Supplementary materials). Data were then
analyzed with Bio-Rad CFX Manager (Bio-Rad) with the
automatic Ct setting for assigning baseline and threshold
for Ct determination. All quantities of the plasma miR-
NAs are expressed as relative quantities based on the 2-
ΔΔCt method in which the relative expression level of
each specific miRNA was calculated using the 2-ΔΔCt
method after normalization to the spiked cel-miRNA-39.
In essence, all significantly changed plasma miRNA
levels reported in this study (out of every human plasma
miRNA (N= 2650)) were quantified using both RNA
sequencing methods and qRT-PCR, adding to the analy-
tical strength and robustness for this type of investigation.
miRNA-based study design
A two-step pilot study was carried out on plasma
samples from age- and sex-matched SMC individuals
(N= 10) recruited from the INSIGHT-preAD study and
dichotomized according to the Aβ-PET imaging status,
either Aβ-PET positive (N= 5) or Aβ-PET negative (N=
5). Using RNA sequencing methods (LC Sciences, LLC,
Houston, TX, US), significant intergroup differences were
found in the plasma miRNA molecular signature
[miRNA-125b, miRNA-146a, miRNA-15b, miRNA-148a,
miRNA-26b, and miRNA-100]. Then, to explore this six-
miRNA panel, the first step pilot study was expanded
(N= 60) by recruiting further age- and sex-matched SMC
individuals of the same cohort, dichotomized as Aβ-PET
imaging positive (N= 30) or negative (N= 30). Outliers
were removed before performing association and com-
parison analysis. The removal of the outliers was based on
the 1.5 IQR (interquartile range=Q3–Q1) rule: data
points outside of the Q1–1.5 IQR and Q3+1.5 IQR are
considered as outliers. Data distribution among data
groups may vary, including the number of outliers.
However, in most cases, no more than two data points
were removed in each group.
PET data acquisition and processing
Aβ-PET investigation was performed at the baseline
visit (“M0”)—as mandatory inclusion criterion—and at
two-year follow-up (“M24”).
Brain amyloid PET scans were acquired 50minutes after
injection of 370 MBq (10 mCi) of 18F-Florbetapir. Brain
18F-FDG scans were obtained 30minutes after injection of
2MBq/kg of 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG).
All acquisitions were performed in a single session on a
Philips Gemini GXL scanner and consisted of 3 ×
5minutes frames with a voxel size of 2 × 2 × 2mm3 35.
Reconstructed PET images are analyzed with a pipeline
developed by the CATI team, a French neuroimaging
platform (http://cati-neuroimaging.com), according to a
method previously described35,38. For longitudinal analy-
sis, the mean activity in supratentorial white matter
(eroded with a radius of three), the pons and
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whole-cerebellum regions were used as a reference for
individual voxel normalization in the partial volume effect
corrected images, as previously suggested39.
Standard uptake value ratios (SUVR) were calculated for
each of 12 bilateral cortical regions of interest (anterior
and posterior cingulate, superior frontal, inferior parietal,
middle temporal cortices, and precuneus), as well as the
global average SUVR.
A threshold of 0.79 obtained from a cross-sectional
pipeline previously published35 was used in the present
study to dichotomize individuals in Aβ-PET positive and
Aβ-PET negative. Correlation analyses were performed
through a longitudinal pipeline deployed through a step-
wise process, previously published by our group40.
The same image-assessment pipeline was applied to
measure brain glucose metabolism on 18F-FDG-PET scans,
in a separate session. Cortical metabolic indices were cal-
culated through Automated Anatomical Labeling atlas—
120 ROIs, from which we selected the bilateral anterior
cingulate cortex, posterior cingulate cortex, inferior parietal
lobe, precuneus, middle temporal cortex, and hippo-
campus, with the pons used as the reference region.
Statistical analysis
The analyses were conducted on a subset (N= 60) of the
INSIGHT-preAD cohort with at least one plasma miRNA
measure. First, we performed a comparison between
Aβ-PET-positive and Aβ-PET-negative individuals seeking
for the difference in plasma miRNA concentrations. Given
the non-Gaussian distribution of miRNAs concentrations,
we performed the Kruskal–Wallis one-way analysis of
variance on ranks test.
Then, we investigated the effects of age, sex, and APOE
ε4 allele carrier status on each plasma miRNA con-
centration at baseline, using linear models (LM).
Then, we tested the association between plasma miR-
NAs concentration, at baseline, and brain Aβ accumula-
tion, measured in terms of baseline and longitudinal
SUVR, at both global and regional levels. Brain regions
were a priori selected based on knowledge of the early
stages of AD. To this aim, we used linear mixed models
(LMM) with random intercept adjusted for age, sex, and
APOE ε4 carrier status. To investigate the longitudinal
association between plasma miRNAs concentration and
brain Aβ accumulation, we tested the interaction effect
between baseline miRNAs concentration and time (miR-
NAs*time) on SUVR changes, over a 2-year follow-up
(“M0” and “M24”).
Then, using a similar approach, we tested the associa-
tion between plasma baseline miRNAs concentration and
both baseline and longitudinal brain hypometabolism,
assessed via 18F-FDG-PET, at the regional level.
Given the non-Gaussian distribution of miRNAs con-
centrations, we carried out permutation tests to
investigate the statistical significance of the model coef-
ficients. This method is more appropriate than parametric
tests for small samples and when the sampling distribu-
tion is unknown41,42. Moreover, differently from rank-
sum tests, permutation tests allow for interpretation of
the results as the difference of median between groups43.
Finally, permutation tests do not require estimation of
statistic values or degrees of freedom. Thus, only P values
were reported. In the present study, 5000 permuted
samplings were run to estimate P values.
The full set of statistical analyses was conducted using
the R software, version 3.6.0. Permutation tests for LM
and LMM were computed using the “pgirmess” and
“predictmeans” libraries, respectively, both available at
http://cran.r-project.org/web/packages. P values < 0.05
were considered significant in all statistical elaborations.
Given the explorative character of the present study, no
correction of P values for multiple comparisons was
applied.
Results
Participant characteristics, Aβ-PET group comparisons for
miRNA concentrations, and association with key biological
factors
Sociodemographic features, APOE ε4 allele frequencies,
Aβ-PET groups, and plasma baseline concentrations of
the six miRNAs of the individuals are reported in Table 1.
Among the miRNAs identified in the total sample of 60
individuals, only miRNA-15b was different between the
two Aβ-PET subgroups, being significantly lower in the
Aβ-PET-positive individuals than Aβ-PET-negative ones
(see Table 2 and Fig. 1).
No association between plasma concentrations of the
six miRNAs and age was found (P > 0.145). Plasma con-
centrations of all miRNAs did not significantly differ
between males and females (P > 0.214).
Likewise, we did not observe a significant APOE ε4 allele
effect on plasma baseline miRNAs concentrations (P >
0.083).
Effect of plasma baseline miRNAs concentrations on the
rate of brain Aβ deposition
We investigated whether plasma baseline concentra-
tions of each miRNA are associated with baseline (M0)
and follow-up (M24) brain Aβ accumulation, at both the
global and regional level.
At M0, we found a negative association between plasma
miRNA-100 concentrations and Aβ-PET SUVR in the
posterior cingulate cortex (left P= 0.046; right P= 0.049).
A negative association was also observed between plasma
miRNA-125b concentrations and Aβ-PET SUVR in the
right anterior cingulate cortex (P= 0.047).
LMM also showed a significantly negative association of
the miRNA-125b*time and miRNA-148a*time interactions
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with Aβ-PET SUVR in the right anterior cingulate cortex
(P= 0.030 and P= 0.045, respectively), over a two-year
follow-up (M0 and M24).
No plasma miRNA was associated with global Aβ-PET
SUVR. We did not find any significant associations
between regional Aβ-PET SUVR and plasma miRNA-15b,
miRNA-26b, and miRNA-146a.
Effect of plasma baseline miRNAs concentrations on brain
metabolism
We investigated whether plasma baseline concentra-
tions of each miRNA were associated with baseline (M0)
and follow-up (M24) of the regional 18F-FDG-PET signal.
We found a significantly negative association between
plasma miRNA-125b concentrations and 18F-FDG-PET
signal in the following regions: posterior cingulate cor-
tex (left P= 0.011; right P= 0.002), anterior cingulate
cortex (left P= 0.006; right P= 0.014), left inferior
parietal cortex (P= 0.048), middle temporal cortex (left
P= 0.027; right P= 0.031), and left hippocampus (P=
0.019), at M0.
Plasma miRNA-148a concentrations negatively corre-
lated with 18F-FDG-PET signal in the right inferior par-
ietal cortex (P= 0.023) and precuneus (left P= 0.030;
right P= 0.049), at M0.
LMM showed a positive miRNA-125b*time interaction
in the right posterior cingulate cortex (P= 0.035), over a
2-year follow-up (M0 and M24).
A significantly negative miRNA-148a*time interaction
was found in the following regions: right anterior cingu-
late cortex (P= 0.045), right inferior parietal cortex (P=
0.020), precuneus (left P= 0.036; right P= 0.037), and
right middle temporal cortex (P= 0.041).
We found a positive effect of the miRNA-15b*time
interaction in the left hippocampus (P= 0.021) and a
negative miRNA-26b*time interaction in the left pre-
cuneus (P= 0.048).
No significant associations with 18F-FDG-PET signal
were found for plasma miRNA-100 and miRNA-146a.
Discussion
To our knowledge, this is the first study investigating
the association of miRNA-based signatures in plasma with
AD core neuroimaging biomarkers of the Aβ pathway and
neuronal metabolism, in a cohort of cognitively normal
individuals with SMC, a condition at increased risk
for AD.
We observed no significant association between age,
sex, APOE ε4 status, and individual miRNA abundance or
speciation, suggesting that miRNAs may represent an
independent variable in specific neurological disease
states. In similar studies analyzing the influence of the
confounding factors age and sex on miRNA profiles from
peripheral blood, it was found that very few single miR-
NAs remained significantly associated with age and sex
Table 1 Sociodemographic features, APOE ε4 allele frequencies, and plasma concentrations of the six identified brain-
enriched miRNAs.
N All individuals Sex APOE ε4 allele
Male Female Carriers Non-carriers
Age, mean ± SD 60 74.23 ± 2.56 74.67 ± 2.90 73.94 ± 2.31 73.54 ± 2.22 74.43 ± 2.64
miRNA15b 57 0.69 (0.30–2.30) 0.59 (0.29–1.84) 0.73 (0.33–2.76) 0.49 (0.28–0.77) 0.78 (0.33–2.39)
miRNA26b 54 0.50 (0.36–1.89) 0.45 (0.37–1.30) 0.59 (0.35–2.31) 0.39 (0.34–0.77) 0.78 (0.40–1.98)
miRNA100 53 0.74 (0.49–1.46) 1.03 (0.49–1.46) 0.70 (0.51–1.48) 0.57 (0.39–1.29) 0.82 (0.51–1.48)
miRNA125b 53 0.78 (0.58–1.11) 0.77 (0.61–1.04) 0.78 (0.54–1.12) 0.65 (0.47–0.79) 0.85 (0.59–1.12)
miRNA146a 53 0.49 (0.32–1.43) 0.47 (0.30–1.19) 0.70 (0.33–1.64) 0.40 (0.28–0.61) 0.79 (0.34–1.64)
miRNA148a 53 0.62 (0.34–1.35) 0.63 (0.36–1.37) 0.51 (0.34–1.33) 0.32 (0.27–0.70) 0.69 (0.36–1.41)
Plasma miRNAs are reported in terms of median (IQ) of concentration (relative quantity).
APOE ε4 Apolipoprotein E ε4 allele, IQ interquartile, miRNA microRNA, N complete observation, SD standard deviation.
Table 2 Comparison of Aβ-PET subgroups for plasma
concentrations of the six identified brain-enriched
miRNAs.
Aβ- Aβ+ p value
miRNA15b 0.83 (0.42–3.14) 0.49 (0.22–1.54) 0.045*
miRNA26b 0.66 (0.41–1.87) 0.46 (0.32–1.88) n.s.
miRNA100 1.03 (0.62–1.48) 0.59 (0.41–1.43) n.s.
miRNA125b 0.76 (0.55–1.09) 0.83 (0.58–1.07) n.s.
miRNA146a 0.75 (0.42–1.62) 0.35 (0.29–1.33) n.s.
miRNA148a 0.62 (0.43–1.34) 0.51 (0.30–1.27) n.s.
*Kruskal–Wallis one-way ANOVA on ranks test. Plasma miRNAs are reported in
terms of median (IQ) of concentration (relative quantity).
PET positron emission tomography, Aβ amyloid beta, n.s. not significant, miRNA
microRNA.
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after adjustment using multiple testing parameters44. This
lack of significant association may also be a reflection of
(I) the observation that many miRNA biomarkers show
discrepant results in independent investigations of the
same disease, and (II) the remarkable heterogeneity of
miRNA complexity and expression patterns in neurolo-
gical disorders, such as those observed across the entire
AD continuum45.
We report significantly lower levels of miRNA-15b in
Aβ-positive individuals than -negative ones.
Interestingly, plasma miRNA-15b, integrated into a
panel of other miRNAs, was found specifically down-
regulated in AD patients compared with both normal
controls46,47 and Parkinson’s disease patients47; it also
positively correlated with cerebrospinal fluid (CSF) Aβ1-42
concentrations47. In another study, the profiling of exo-
somal miRNAs extracted from serum samples disclosed
miRNA-15b downregulated expression in AD patients
compared to healthy control individuals48.
Such evidence led to infer a potential link between
miRNA-15b and protective dynamics counteracting the
dysregulation of the Aβ pathway. This hypothesis is
supported by studies conducted in SH-SY5Y/APPswe
neuroblastoma cell lines that reported an association of
miRNA-15b with: (I) inhibition of brain Aβ accumula-
tion, by directly downregulating β-site amyloid precursor
protein cleaving enzyme 1 (BACE1) protein expression
or (I) attenuation of Aβ-induced secretion/expression of
pro-inflammatory cytokines, by suppressing the pro-
inflammatory nuclear factor kappa-light-chain-enhancer
of activated B cells signaling pathway activation49. This
experimentally inferred anti-Aβ effect alongside the
statistical difference between our two Aβ-PET subgroups
of individuals, suggested an association between miRNA-
15b and regional Aβ-PET SUVRs that we did not find.
Although there may be a neurobiological explanation, we
cannot rule out a statistical Type II error related to the
small sample size (see also below).
We also found a positive association between miRNA-
15b concentrations and levels of neuronal metabolism
(18F-FDG-PET SUVR) in the hippocampus. Although an
interpretation of this finding is rather challenging, it is
worth noting that miRNA-15b is known for its regulatory
activity of cortical development and its involvement in the
expansion and differentiation of cortical neural progenitor
cells50.
We showed associations of miRNA-125b and miRNA-
148a concentrations with Aβ-PET SUVR and miRNA-15b
with 18F-FDG-PET signal in some early AD-related brain
regions and the hippocampus.
In the present study, the negative baseline association
between plasma miRNA-125b and miRNA-100 con-
centrations and Aβ-PET SUVR in the right anterior cin-
gulate cortex and the bilateral posterior cingulate cortex
indicate a potential modulatory role of these miRNAs on
the Aβ pathway, tracked at the fibrils and plaques phase
when investigated with the current Aβ-PET radiotracers.
The negative association of miRNA-125b and miRNA-
148a concentrations with baseline and follow-up Aβ-PET
SUVR in the right anterior cingulate cortex strengthens
such a hypothesis.
The negative associations between these three miRNAs
(miRNA-125b, miRNA-100, and miRNA148a) and base-
line and follow-up levels of Aβ-PET radiotracer uptake
support a knowledge-based, albeit speculative, hypothesis
that the miRNAs in question are linked to molecular
mechanisms that inhibit Aβ deposition.
Fig. 1 miRNA15b is significantly lower in the Aβ-PET negative
subgroup compared with the Aβ-PET positive. *Kruskal–Wallis
one-way ANOVA on ranks test; p value: 0.045 (see Table 1 for
descriptive data). Plasma miR-15b concentration is reported in terms
of relative quantity. PET positron emission tomography, Aβ amyloid
beta, n.s. not significant, miRNA microRNA.
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In an attempt to address our results from an over-
arching neurobiological standpoint, we outline that
miRNA-125b is the miRNA more extensively investigated
in the AD human brain and biofluids and experimental
models of the disease as well. Studies conducted in pri-
mary mouse cortical neurons (MCN) and neuroblastoma
Neuro2a (N2a) cells show that miRNA-125b binds to the
BACE1 protein with an inhibitory effect on its expression
levels and mitigates Aβ-induced neurotoxicity51. In par-
ticular, BACE1 protein acted as a target of miRNA-125b
and was negatively modulated by this miRNA in both
MCN and N2a cells. BACE1 restoration inhibited the
effect of miRNA-125b on Aβ-induced neurotoxicity, thus
indicating that miRNA-125b might repress AD develop-
ment by reducing BACE1 expression. Moreover, the
authors showed that toxic downstream effects of Aβ
species, such as apoptotic rate, promotion of caspase-3
activity (crucial for neuronal apoptosis), and oxidative
stress—were all decreased. The same study also reported
that miRNA-125b and BACE1 mRNA serum expression
levels were respectively reduced and increased in patients
with sporadic AD compared to age-matched healthy
individuals. A negative correlation between miRNA-125b
and BACE1 mRNA serum expression levels was found in
AD patients51.
CSF and blood (serum)-based studies reported down-
regulation of miRNA-125b in AD patients compared with
a cohort of non-inflammatory and inflammatory neuro-
logical disease controls52 and to healthy controls53. The
same result was reported in two independent studies
conducted in either CSF or plasma54.
By contrast, our miRNA-125b-related result seems to
counteract a previous post-mortem study reporting that
miRNA-125b was significantly and distinctively upregu-
lated in AD temporal lobe neocortex, potentially con-
tributing to the neurodegenerative process of the
disease55. Another study reported that miRNA-125b is
also overexpressed in the hippocampus in AD late stages
(Braak stages V, VI)56.
The studies mentioned above support the negative (five
out of eight regions, with only one region proving posi-
tively associated and counteracting this trend of associa-
tions) association we found between miRNA-125b and
18F-FDG-PET indexes in multiple brain regions involved
in early AD. This finding is in line with experimental
studies that showed an association between miRNA-125b
and synaptic toxicity in cultured hippocampal neurons57
as well as between miRNA-125b overexpression and
impairment of synaptic remodeling and transmission
coupled with inhibition of the long-term potentiation
(LTP) activation58.
Moreover, miRNA-125b, one of the most highly
expressed microRNAs in the human brain and retina, was
associated with kinase/phosphatase activity inbalance,
increased tau phosphorylation and its downstream per-
turbation of the synaptic activity59.
In the present study, the absence of converters from
SMC to mild cognitive impairment (MCI) (or even overt
dementia) does not allow drawing any meaningful bio-
logical or clinical conclusion on the role of miRNA-125b
in AD; however, our PET-based results coupled with
the existing literature suggest that miRNA125b may be
linked to Aβ-independent neurotoxic pathways. The
limitations of the present exploratory study will need to
be overcome in future investigations with longer follow-
up and higher rates of conversion to MCI and AD
dementia to untangle the role, either mono-dimensional
or dualistic, of miRNA-125b.
There is no extensive experimental evidence to explain
the unprecedented association we here report for miRNA-
148a and miRNA-100 with biomarkers charting the Aβ
pathway and neuronal metabolism. However, these miR-
NAs have been previously investigated in AD, with the
former upregulated in AD patients60, and miRNA-100
found lower in AD versus non-demented controls61.
Neurobiological studies pointed out miRNA-148a as
upregulated in the hippocampus of 3xTgAD mice versus
their age-matched controls62, and it was highly con-
centrated in synapses63 and downregulated the expres-
sion of Ca2+/calmodulin-dependent protein kinase IIα64,
a key protein for Calcium homeostasis. Calcium dysre-
gulation has been demonstrated to potentially occur
upstream to brain proteinopathies with Aβ monomers
production and tau hyperphosphorylation that can be
triggered by a sustained increase of cytosolic Calcium
concentrations over basal levels65. From a functional
standpoint, miRNA-148a upregulation was associated
with impairment of LTP that underlies memory dys-
function in AD64.
Regarding the positive association found between
miRNA-148a and 18F-FDG-PET SUVR, at both baseline
and follow-up, the interpretation of this data is rather
challenging given the lack of experimental evidence about
this miRNA and neuronal functions.
Limitations
The study presents some caveats that need to be
addressed. First, the restricted sample size of the first step
of the pilot study (N= 10) potentially limited the number
of miRNAs dysregulated that were detected between
groups. Moreover, the relatively small sample size of the
second step pilot study (N= 60) limited the general-
izability of our conclusions. The absence of converters to
MCI or even dementia stage constrains the clinical con-
clusions that can be drawn. Future studies in larger
cohorts of SMC individuals, with extensive follow-up, are
needed to corroborate or disconfirm the findings of the
present pilot data.
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We performed a priori investigation on selected brain
regions rather than executing a whole-brain exploratory
strategy. Although the latter approach might have con-
tributed to untangle patterns of brain Aβ accumulation
and synaptic activity, we could not run it owing to sta-
tistical reasons (i.e., statistical power).
Finally, our investigation was exclusively performed on
a sample of Caucasian individuals; hence, replicating our
findings in different ethnic populations would be
remarkable.
To increase the clinical meaningfulness of the present
exploratory study results, we intend to carry out a sub-
sequent study in a larger population of INSIGHT-preAD
cognitively healthy individuals, possibly employing an
independent validation cohort, and including (i) blood-
based biomarkers charting AD pathophysiological altera-
tions and (ii) longer follow-up of neuroimaging and cog-
nitive measures. We set out to explore whether plasma
miRNA can predict AD clinical-biological trajectories;
thus, representing a candidate non-invasive and accessible
screening and prognostic tool. If our results were corro-
borated, plasma miRNA could be integrated into a blood-
based biomarker matrix for precision medicine-oriented
large-scale investigation of cognitively healthy individuals
at increased risk of developing rapid AD pathophysiolo-
gical and cognitive impairment, a highly suitable popu-
lation for disease-modifying therapeutic approaches when
these will be available.
Conclusions
This is the first exploratory study reporting significant
associations between plasma concentrations of a signature
of miRNAs we identified and AD core neuroimaging
biomarkers of the Aβ pathway and neuronal metabolism
in a cohort of SMC individuals, a condition associated
with increased risk of AD. In particular, our study pro-
vides preliminary evidence in vivo about the potential role
of miRNAs -125b and -15b, as candidate miRNA bio-
marker of AD pathophysiology.
In summary, our findings are consistent with the
endevour of generating insights about the roles that cir-
culating miRNAs may play for AD pathophysiology.
Results turning out of this research line may inform
precision-medicine oriented pharmacological trials that
take into account the entire biological profile of the single
patient. Such an approach could be then generalized to
the broad spectrum of neurodegenerative diseases by
developing pathway-based therapies in biologically ideal
individuals, in line with the precision medicine paradigm
shift.
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